1471 related articles for article (PubMed ID: 18758474)
41. Liposomal nanomedicines.
Fenske DB; Cullis PR
Expert Opin Drug Deliv; 2008 Jan; 5(1):25-44. PubMed ID: 18095927
[TBL] [Abstract][Full Text] [Related]
42. Clinical trials and biomarker development with molecularly targeted agents and radiotherapy.
Dhani N; Siu LL
Cancer Metastasis Rev; 2008 Sep; 27(3):339-49. PubMed ID: 18379730
[TBL] [Abstract][Full Text] [Related]
43. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
Moreno-Aspitia A; Perez EA
Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
[TBL] [Abstract][Full Text] [Related]
44. Emerging nanotherapeutic strategies in breast cancer.
Blanco E; Ferrari M
Breast; 2014 Feb; 23(1):10-8. PubMed ID: 24215984
[TBL] [Abstract][Full Text] [Related]
45. Shedding light on tumors using nanoparticles.
Rao J
ACS Nano; 2008 Oct; 2(10):1984-6. PubMed ID: 19206441
[TBL] [Abstract][Full Text] [Related]
46. Nanodiamonds as vehicles for systemic and localized drug delivery.
Lam R; Ho D
Expert Opin Drug Deliv; 2009 Sep; 6(9):883-95. PubMed ID: 19637985
[TBL] [Abstract][Full Text] [Related]
47. AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 3.
Collins T
IDrugs; 2007 Dec; 10(12):840-3. PubMed ID: 18041675
[No Abstract] [Full Text] [Related]
48. Nanotechnology. Nanoparticle Trojan horses gallop from the lab into the clinic.
Service RF
Science; 2010 Oct; 330(6002):314-5. PubMed ID: 20947742
[No Abstract] [Full Text] [Related]
49. Delivering cytokines at tumor site: The immunocytokine-conjugated anti-EDB-fibronectin antibody case.
Ronca R; Sozzani S; Presta M; Alessi P
Immunobiology; 2009; 214(9-10):800-10. PubMed ID: 19625102
[TBL] [Abstract][Full Text] [Related]
50. The epothilones: how pharmacology relates to clinical utility.
Michaud LB
Ann Pharmacother; 2009 Jul; 43(7):1294-309. PubMed ID: 19584389
[TBL] [Abstract][Full Text] [Related]
51. Recent Findings on Nanotechnology-based Therapeutic Strategies Against Hepatocellular Carcinoma.
Samie HAA; Saeed M; Faisal SM; Kausar MA; Kamal MA
Curr Drug Metab; 2019; 20(4):283-291. PubMed ID: 30854953
[TBL] [Abstract][Full Text] [Related]
52. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation.
Tseng CL; Su WY; Yen KC; Yang KC; Lin FH
Biomaterials; 2009 Jul; 30(20):3476-85. PubMed ID: 19345990
[TBL] [Abstract][Full Text] [Related]
53. Nano cancer therapy strategies.
Tiwari M
J Cancer Res Ther; 2012; 8(1):19-22. PubMed ID: 22531508
[TBL] [Abstract][Full Text] [Related]
54. Technology evaluation: electroporation therapy, Genetronics Inc.
Orr RM
Curr Opin Mol Ther; 2000 Apr; 2(2):205-10. PubMed ID: 11249643
[TBL] [Abstract][Full Text] [Related]
55. Lean and mean: nanoparticle-based delivery improves performance of cancer drugs.
Shekhar C
Chem Biol; 2009 Apr; 16(4):349-50. PubMed ID: 19389621
[No Abstract] [Full Text] [Related]
56. Nanoparticles in cancer chemotherapy.
Banerjee D; Sengupta S
Prog Mol Biol Transl Sci; 2011; 104():489-507. PubMed ID: 22093227
[TBL] [Abstract][Full Text] [Related]
57. Block copolymer micelles for delivery of cancer therapy: transport at the whole body, tissue and cellular levels.
Mikhail AS; Allen C
J Control Release; 2009 Sep; 138(3):214-23. PubMed ID: 19376167
[TBL] [Abstract][Full Text] [Related]
58. Electrochemotherapy: an emerging cancer treatment.
Sadadcharam M; Soden DM; O'sullivan GC
Int J Hyperthermia; 2008 May; 24(3):263-73. PubMed ID: 18393004
[TBL] [Abstract][Full Text] [Related]
59. Nanoparticle formulations in pulmonary drug delivery.
Bailey MM; Berkland CJ
Med Res Rev; 2009 Jan; 29(1):196-212. PubMed ID: 18958847
[TBL] [Abstract][Full Text] [Related]
60. The Hedgehog signalling pathway as a therapeutic target in early breast cancer development.
O'Toole SA; Swarbrick A; Sutherland RL
Expert Opin Ther Targets; 2009 Sep; 13(9):1095-103. PubMed ID: 19659449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
